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ABSTRACT The multidrug-resistance associated protein
MRP is a 180- to 195-kDa membrane protein associated with
resistance of human tumor cells to cytotoxic drugs. We have
investigated how MRP confers drug resistance in SW-1573
human lung carcinoma cells by generating a subline stably
transfected with an expression vector containing MRP cDNA.
MRP-overexpressing SW-1573 cells are resistant to doxorubi-
cin, daunorubicin, vincristine, VP-16, colchicine, and rhoda-
mine 123, but not to 4'-(9-acridinylamino)methanesulfon-m-
anisidide or taxol. The intracellular accumulation of drug
(daunorubicin, vincristine, and VP-16) is decreased and the
efflux of drug (daunorubicin) is increased in the ransfectant.
The decreased accumulation of daunorubicin is abolished by
permeabillzation of the plasma membrane with digitonin,
showing that MRP can lower the intracellular daunorubicin
level against a concentration gradient. Anti-MRP antisera
predominantly stain the plasma membrane of MRP-
overexpressing cells. We conclude that MRP is a plasma
membrane drug-efflux pump.
Cells selected for resistance to a single cytotoxic drug may
become crossresistant to a whole range of drugs with differ-
ent structures and cellular targets. This phenomenon is called
multidrug resistance (MDR). The classic form ofMDR is due
to an increased activity of P-glycoprotein (Pgp), encoded by
the human MDR] gene (1-4) (standard gene symbol, PGYI).
This large glycoprotein is located in the plasma membrane
and can extrude a range ofhydrophobic natural product drugs
from the cell against a concentration gradient (1-5). An
increase in Pgp activity can result in lowered intracellular
drug concentration and, hence, in drug resistance.
Increased Pgp is not the only cause of MDR, however.
Several cell lines selected for resistance do not contain
increased amounts of Pgp but nevertheless are resistant to a
broad range of natural-product drugs (6-9). In one of these
non-Pgp MDR lines, the H69AR small-cell lung carcinoma
(SCLC) line, Cole et al. (10) found amplification and in-
creased expression of a novel gene, the MRP (MDR-
associated protein) gene. Overexpression of MRP has since
been observed in several other (11-14), but not all (11),
non-Pgp MDR cell lines. Transfection of HeLa cells with an
expression vector containing the MRP cDNA results in the
acquisition of resistance to doxorubicin, vincristine, and
VP-16, but not cisplatin (15). We show here that transfection
of the MRP cDNA into human lung carcinoma cells also
results in MDR.
These experiments prove that MRP is a drug-resistance
gene, but they do not answer the question how MRP acts. As
MRP belongs to the ABC superfamily of transporter proteins
(10, 16), it could simply act like Pgp, as a plasma membrane
pump extruding drugs. Indeed, decreased drug accumulation
has been reported for several non-Pgp MDR cell lines that
were later found to overexpress MRP (7, 11-14). A major
exception, however, is theMDR H69AR cell line in which the
MRP gene was discovered (10). Drug accumulation was
reported to be the same as in the parental cell line and this led
Cole et al. (10, 17, 18) to consider other mechanisms than
decreased drug accumulation for MRP action. Moreover, the
subcellular location ofMRP did not seem to be similar to that
of a plasma membrane transporter such as Pgp. A 190-kDa
protein detected in non-Pgp MDR cells and thought to be
MRP was found mainly in the endoplasmic reticulum, rather
than in the plasma membrane (13, 14).
To analyze the mechanism of action ofMRP, we examined
the effect of MRP overexpression on drug resistance and
drug accumulation in SW-1573 lung carcinoma cells. In
addition, we have raised antibodies against segments ofMRP
and used these to determine its main cellular location.
MATERIALS AND METHODS
Cell Lines. The drug-sensitive and doxorubicin-selected
MDR sublines of the non-SCLC cell line SW-1573 and the
SCLC line GLC4 have been described (7-9). The MDR3
Pgp-expressing cell line VOlVOl and the control cell line
FVB c are simian virus 40-immortalized mouse ear fibro-
blasts obtained from FVB mice transgenic for the human
MDR3 gene and normal FVB mice, respectively (19).
Vector Construction and Transfection. A DNA fragment
containing the complete predicted MRP open reading frame
(10, 15) plus 115 nt of 5' and 800 nt of 3' noncoding sequence
was constructed in the expression vectors pJ3fl (20) and
pRc/RSV (Invitrogen). All cDNA fragments used for the
assembly of the MRP cDNA were sequenced and the integ-
rity of the MRP cDNA fragment in the resulting expression
vectors, pJ3fl-MRP and pRc/RSV-MRP (Fig. 1), was as-
sessed by restriction enzyme mapping and DNA sequence
analysis of the cloning junctions. Transfection of SW-
1573/S1 cells with pRc/RSV-MRP DNA or African green
monkey kidney COS-7 cells with pJ3fl-MRP DNA followed
the standard calcium phosphate precipitation technique (21).
Stable transfectants in S1 were selected for 3 weeks in
medium with G418 at 800 iig/ml and propagated for further
analysis with G418 at 200 ug/ml. COS-7 cells were
trypsinized 48 hr after transfection and analyzed by immu-
nocytochemistry.
MRP Fusion Proteins and Immunization. Two fusion genes
consisting of the gene for the Escherichia coli maltose-
binding protein and two different segments of the MRP
cDNA were constructed in the plasmid vector pMal-c (22).
Abbreviations: MDR, multidrug resistance (resistant); Pgp, P-gly-
coprotein; SCLC, small-cell lung cancer; pH;, intracellular pH;
m-AMSA, 4'-(9-acridinylamino)methanesulfon-m-anisidide.
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FIG. 1. MRP expression vectors. (Left) pJ3fl-MRP, containing
the MRP cDNA under control of simian virus 40 (SV40) regulatory
elements. O/P, SV40 origin and early promoter; IVS, SV40 t-antigen
intervening sequence; poly A, SV40 T-antigen polyadenylylation
signal; Ampr, 1-lactamase gene; ori, origin of replication. (Right)
pRc/RSV-MRP, containing the MRP cDNA under control of the
Rous sarcoma virus long terminal repeat (RSV LTR). BGH poly A,
bovine growth hormone gene polyadenylylation signal; Neor, neo-
mycin-resistance gene.
The MRP sequences in the expression plasmids encoded aa
780-944 (fusion protein II) or 1294-1431 plus 14%-1531
(fusion protein III) of MRP. The fusion proteins were pro-
duced in E. coli JM101 and purified by amylose resin affinity
chromatography (22). Guinea pigs (Sewall-Wright inbred
strain) received sub- and intracutaneous injections of 200 Pg
of purified fusion protein II or III emulsified in Freund's
complete adjuvant (Bacto, Detroit, MI). After 2 and 4 weeks
booster injections with the same dose of immunogen in
Freund's incomplete adjuvant were given intracutaneously,
and after an additional 2 weeks the animals were bled.
Immunocytochemistry. Cytocentrifuge preparations of tu-
mor cell lines were air-dried overnight, fixed for 10 min in
acetone or 4% (vol/vol) paraformaldehyde in phosphate-
buffered saline and incubated for 60 min with diluted antisera.
Antibody binding was detected with a biotinylated mouse
anti-guinea pig monoclonal antibody (Dako) and streptavidin-
conjugated horseradish peroxidase (Zymed). The slides were
developed with 3-amino-9-ethylcarbazole, counterstained
with hematoxylin, and mounted with Aquamount.
Protein Blots. Total cell lysates were made by lysing
harvested cells in 10mM KCl/1.5 mM MgCl2/10 mM Tris Cl,
pH 7.4/0.5% (wt/vol) SDS supplemented with 1 mM phe-
nylmethylsulfonyl fluoride, leupeptin (2 ug/ml), pepstatin (1
pg/ml), and aprotinin (2 ,ug/ml). DNA was sheared by
sonication and samples containing 25 gg of protein were
fractionated by SDS/7.5% PAGE and then transferred onto
a nitrocellulose filter by electroblotting. Immunoreactivity of
proteins with the antisera against the fusion proteins was
visualized with peroxidase-conjugated rabbit anti-guinea pig
immunoglobulins (Dako) and 3,3'-diaminobenzidine and
4-chloro-1-naphthol substrate. P-glycoproteins were de-
tected by using the monoclonal antibody C219, rabbit anti-
mouse IgG, and 1251-labeled protein A. For glycosylation
studies of MRP, membrane-enriched protein fractions were
prepared and treated with N-glycanase (a mixture of endogly-
cosidase F and peptide:N-glycosidase F) (Boehringer Mann-
heim) (21).
Drug Accumulation. Steady-state accumulation of radiola-
beled daunorubicin, vincristine, and VP-16 was measured
according to Skovsgaard (23), as modified by Broxterman et
al. (24). Cells in the logarithmic phase of growth (0.2 x 106
cells per ml) were incubated at 37°C with 3H-labeled dauno-
rubicin, vincristine, or VP-16. After 75 min ice-cold phos-
phate-buffered saline was added and after two cold washes
radioactivity was determined by liquid scintillation counting.
The cellular influx of daunorubicin was measured by moni-
toring the fluorescence decrease after addition of cells to
daunorubicin with a fluorescence monitor (FluoroMax; Spex
Industries, Metuchen, NJ) at excitation and emission wave-
lengths of 488 and 560 nm, respectively. Intracellular pH
(pHi) was measured with 2'7'-bis(2-carboxyethyl)-5 (and
6)-carboxyfluorescein (BCECF) (25).
RESULTS
Cloning and DNA Sequence Analysis ofMRP cDNA. MRP
encodes an mRNA of =6.5 kb encompassing a continuous
open reading frame of 1531 aa (10, 15). We have isolated a set
of overlapping cDNA clones by hybridization screening of a
cDNA library of adenovirus-transformed human retinal cells
(RCA) and by reverse transcription-PCR ofmRNA from the
lung cancer cell line GLC4/ADR. Together these clones
covered the complete predicted coding region of the MRP
mRNA plus 137 nt of 5' and 1137 nt of 3' noncoding sequence;
916 nt of 3' noncoding sequence were not published previ-
ously and have been deposited in the GenBank database
(accession no. X78338). The cDNA clones obtained from the
RCA cDNA library differ in a few nucleotides from the
sequence published by Cole et al. (10): five ofthese are silent
variations (T-1021-* C; T-1258-* C; T-1880-- C; C-1900 --
T; A-1907 C), whereas two lead to amino acid changes
[C-546 -* T (Thr-117 -* Met); T-2250 -+ C (Leu-685 -> Ser)].
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FIG. 2. Immunoblot analysis of total protein of cell lines with
increased levels of MRP (GLC4/ADR), MDR] Pgp (1R500-0), or
MDR3 Pgp (VOlVO1) and of the corresponding parental cell lines(GLC4, S1, and FVB-c). Protein blots were incubated with antiserum
against MRP fusion protein II (A), antiserum against MRP fusion
protein III (B), or the Pgp-reactive monoclonal antibody C219 (C).
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As the variation at aa 685 is in the highly conserved Walker
A consensus motif in the amino-proximal nucleotide-binding
domain (10, 16), we checked whether it was also present in
cDNA from GLC4/ADR cells. This was the case. Since the
reconstructed cDNA from the RCA cDNA clones encodes a
functional MRP (see below), we conclude that the two amino
acid changes do not impair the activity of MRP.
Generation of Anti-MRP Polyclonal Antisera. To examine
the expression level and the cellular localization ofMRP, we
prepared polyclonal antisera against two bacterial fusion
proteins containing different fragments of MRP. The first
fusion protein contained the "linker" domain that connects
the two halves of the protein (fusion protein II) (10). The
second contained the carboxyl-terminal end and part of the
predicted carboxyl-proximal nucleotide binding domain of
MRP (fusion protein III) (10). The specificity of the antisera
was determined on protein blots (Fig. 2) and on cytocentri-
fuge preparations oftumor cells and of African green monkey
kidney COS-7 cells that transiently overexpress MRP (Fig.
3).
On immunoblots both antisera detected a protein of 190-
195 kDa in total protein isolates of the GLC4/ADR cells, but
not ofthe parental drug-sensitive cell line GLC4 (Fig. 2). This
is in agreement with the massive increase ofMRPmRNA and
MRP gene-copy number in the GLC4/ADR cells, relative to
the low basal MRP mRNA level in GLC4 (11). The sera did
not crossreact with the human MDR] or MDR3 Pgps (Fig. 2)
but did crossreact with several small proteins not affected by
the level of MRP and present in all cell lines. In addition, one
of the antisera also reacted with a band of about 180 kDa in
the two mouse cell lines (Fig. 2B). These bands did not
precisely comigrate with Pgp and they might be mouse MRP.
In cytological preparations we saw strong staining with
GLC4/ADR cells (Fig. 3 B and C) and other MRP-
overexpressing cell lines, including the fibrosarcoma cell line
HT1080/DR4 (12) and the leukemia cell line HL60/ADR (13)
(data not shown), but not with the respective parental drug-
sensitive cell lines (Fig. 3A). Staining was primarily over the
plasma membrane. In most of the cells a dense spot near the
nucleus was also seen, probably corresponding to the Golgi
network. This may represent nonfunctional MRP or protein
that is on its way to the plasma membrane. Both antisera
showed the same staining pattern and specificity. We also
saw strong reaction with COS-7 cells that were transiently
transfected with the MRP expression vector pJ3Ql-MRP
(Figs. 1 and 3G), but not with "mock"-transfected cells (Fig.
3F).
Overexpression of MRP in SW-1573 Cells. To make stable
transfectants in SW-1573 cells we cloned the MRP cDNA
behind the Rous sarcoma virus promoter in the expression
vector pRc/RSV (Fig. 1B). This vector also contains the
bacterial neo gene allowing the selection of transfected cells
with the neomycin analogue G418. pRc/RSV-MRP (Fig. 1B)
was transfected into SW-1573/S1 cells, and after 3 weeks of
selection with G418, 40 colonies were picked randomly and
analyzed for MRP expression. Only 5 clones showed in-
creased MRP mRNA, as measured by an RNase protection
assay (11), indicating that in the other clones only the neo
gene was correctly integrated. Of the 5 clones with increased
MRP mRNA, 1, designated S1(MRP), also showed increased
MRP in immunoblot analysis (Fig. 4A). In a second trans-
fection experiment 1 of 30 G418-resistant transfectants ana-
lyzed overexpressed MRP [S1(MRP)-2, Fig. 4A]. Both trans-
fectants with raised MRP mRNA levels were MDR, whereas
G418-resistant clones that did not overexpressMRP were not
(Table 1).
Glycosylation of MRP. MRPs from the transfectants comi-
grated with MRP present in S1 cells in SDS/PAGE and their
mobility corresponded to ==180 kDa (Fig. 4). MRPs from the
resistant GLC4 and SW-1573 sublines all migrated slower
(Fig. 4B). After treatment with N-glycanase, the two types of
MRP both decreased in apparent mass to -170 kDa (Fig. 4C),
in agreement with the 172 kDa predicted from the primary
amino acid sequence of MRP. This suggests that the differ-
ence in mobility seen in untreated protein samples is due to
a difference in glycosylation.
Location ofMRP in the Cell. In cytocentrifuge preparations
both anti-MRP antisera mainly stained the plasma membrane
of S1(MRP) cells (Fig. 3E). There was also cytoplasmic
staining, however, mostly homogeneous, but in some cells
present as a concentric ring around the nucleus. Whether this
ring represents the endoplasmic reticulum or the nuclear
membrane remains to be determined. The relative fraction of
MRP present in the plasma membrane of S1(MRP) seemed
lower than in GLC4/ADR, suggesting that the routing of
nascent MRP may differ in the two cell types. Untransfected
S1 cells did not stain (Fig. 3D), confirming the specificity of
the antisera for MRP.
Mechanism of MRP-Mediated MDR. The resistance spec-
trum of the MRP-overexpressing transfectants was com-
pared with that of untrarisfected SW-1573/S1 cells in clono-
-C.1;A
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FIG. 3. Immunochemical staining of cytocen-
trifuge preparations of MRP-overexpressing
cells. (A) Drug-sensitive GLC4 cells. (B and C)
-.-° Drug-resistant MRP-overexpressing GLC4/ADR
cells (two different magnifications). (D) Drug-
sensitive SW-1573/S1 cells. (E) S1(MRP), an
Gt AMRP-overexpressing transfectant of S1. (F)COS-7 cells transfected with plasmid DNA lack-
ing MRP cDNA sequences ("mock" transfec-
tion). (G) COS-7 cells transfected-with pJ3Ql-MRP
DNA (Fig. 1). The stained cells are the transiently
transfected cells that highly overproduce MRP. In
the COS-7 cells most MRP is in the cytoplasm.
Therefore, the COS-7 expression system may not
be suitable for functional studies on MRP. Slides
were stained with antiserum against MRP fusion
- protein III. Staining with antiserum against fusion
Dole..z? protein II gave similar results. (Bars = 50 AM.)
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FIG. 4. Immunoblot analysis of MRP in untransfected S1 cells
and MRP-overexpressing transfectants [S1(MRP) and S1(MRP)-2]
(A) and drug-sensitive (GLC4 and S1) and drug-resistant lung cancer
cell lines [GLC4/ADR, S1(MRP), lRSOb, 2R120, and 2R160] (B) and
of MRP glycosylation in GLC4/ADR and S1(MRP) cells (C). +,
Membrane-enriched protein fractions treated with N-glycanase; -,
untreated control samples. Migration of protein markers of 117 and
200 kDa is indicated with dots at left and with bars at right. Blots were
stained with the anti-MRP monoclonal antibody MRPrl (M.J.F.,
R.J.S., and G.J.R.Z., unpublished data) (A) or with polyclonal
antiserum against MRP fusion protein III (B and C).
genic survival assays. The results for S1(MRP) are summa-
rized in Table 1. Overexpression of MRP in SW-1573 cells
increases resistance to doxorubicin, vincristine, and VP-16
(Table 1), as also reported by Grant et al. (15) for HeLa cells.
In addition we found increased resistance to daunorubicin,
colchicine, and rhodamine 123, but not to m-AMSA and taxol
(Table 1). S1(MRP)-2 was about 2-fold resistant to doxoru-
bicin, vincristine, and VP-16, and not to m-AMSA, thus
confirming the results for S1(MRP).
Resistance was associated with a decreased steady-state
accumulation of drug (Table 2). The mechanism of decreased
drug accumulation in S1(MRP) was examined in detail for
daunorubicin. As this is a weak base, its accumulation could
be decreased by an increase in pHi (26). This was not the
case, as we found a pHi of 7.27 ± 0.13 (mean + SD; n = 3)
in S1 cells and a pHi of 7.30 ± 0.10 in S1(MRP) cells. A
decrease in drug accumulation could also be caused by a
decrease in cellular binding sites. To test this possibility, we
Table 1. Resistance spectrum of the MRP transfectant S1(MRP)
Drug Relative resistance
Doxorubicin 2.7 ± 0.4
Daunorubicin 3.2 ± 0.8
Vincristine 5.3 ± 1.3
VP-16 4.9 ± 1.1
m-AMSA* 1.1 ± 0.1
Colchicine 3.6 ± 0.1
Rhodamine 123 4.1 ± 0.3
Taxol 1.0 ± 0.1
Resistance was determined in clonogenic survival assays (8).
Relative resistance = ICso Sl(MRP)/IC50 Si (ICso, inhibitory con-
centration where 50%o of the cells survive). The values are the means
+ SD of at least three experiments, each performed in duplicate.
*4'-(9-Acridinylamino)methanesulfon-m-anisidide.
selectively permeabilized the cellular plasma membrane with
digitonin (see ref. 25). Upon addition of digitonin, the accu-
mulation of daunorubicin in S1(MRP) cells became equal to
that in S1 cells (Table 2), showing that the accumulation
deficit in S1(MRP) was not due to fewer cellular binding sites.
This was confirmed by an experiment where the uptake of
daunorubicin into S1 and S1(MRP) was followed in time and
compared with the uptake into the 2R120 subline (Fig. 5). The
fluorescence decrease represents mainly quenching of
daunorubicin by binding to the DNA (27). The accumulation
of daunorubicin was lower in S1(MRP) and 2R120 cells than
in S1 cells, in agreement with Table 2. Upon addition of
digitonin, S1(MRP) and 2R120 showed a large increase in
DNA binding (Fig. 5). These results demonstrate that the
decreased accumulation of daunorubicin in the MRP-
overexpressing cells was not due to a passive redistribution
of drug, but due to an active process. When we therefore
tested daunorubicin efflux from transfected and control cells;
the efflux of daunorubicin was faster from S1(MRP) than
from S1 cells (Fig. 6). We conclude that MRP can mediate the
active extrusion of daunorubicin from cells.
DISCUSSION
Our results show that MRP is remarkably similar to the
drug-transporting Pgps in its mode of action. (i) Like Pgp,
MRP can cause resistance to a range of hydrophobic drugs.
(ii) MRP is predominantly located in the plasma membrane.
(iii) MRP can decrease drug accumulation in the cell and this
decrease is abolished by permeabilization of the plasma
membrane. (iv) MRP can increase the effiux of drugs from
cells. We therefore think that MRP acts as a drug pump, like
Pgp, extruding hydrophobic compounds from cells against a
concentration gradient. Presumably the two ATP-binding
motifs in MRP allow the protein, just like Pgp, to use ATP
hydrolysis for active transport.
The drug-resistance spectra associated with MRP and
MDR] overexpression are remarkably similar, given the
Table 2. Accumulation of daunorubicin (0.5 p;M, 75 min),
vincristine (0.5 ,uM, 75 min) and VP-16 (5 uM, 75 min) in
untransfected S1 cells and the MRP transfectant S1(MRP)
pmol per 106 cells
Daunorubicin*
Cell line - digitonin + digitonint Vincristine* VP-16*
S1 367 ± 30 292 ± 39 28.8 ± 3.6 13.0
S1(MRP) 211 ± 22 295 ± 25 16.1 ± 4.4 5.5
*Mean ± SD of four independent experiments, each performed in
quadruplicate.
tDigitonin (20 ,uM) was added S min before the end ofthe incubation.
WMean of two independent experiments, each performed in quadru-
plicate. Variation was <2 pmol per 106 cells.
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FIG. 5. Time course of daunorubicin uptake by SW-1573 cell
lines. One million S1, S1(MRP), or 2R120 cells were added to 2.5 ml
of medium containing 1 IAM daunorubicin. The decrease in fluores-
cence due to increased influx of daunorubicin and binding to DNA
was recorded. After 90 min of incubation, digitonin (20 AM) was
added to the medium.
large difference in sequence between MRP and the MDRJ-
encoded Pgp (10). Nevertheless, there are also important
differences between MRP and MDR] Pgp in the drugs that
they transport or interact with. We found no resistance to
taxol in lung carcinoma cells transfected with MRP cDNA
(Table 1), whereas mouse bone marrow cells transgenic for
MDR] are highly resistant (28). In a preliminary search for
reversal agents of MRP-mediated MDR, we found that the
decreased accumulation of daunorubicin in the MRP trans-
fectant was not affected by cyclosporin A, an effective
reversal agent of Pgp-mediated MDR. In contrast, the isofla-
vinoid genistein, a drug that does not inhibit MDR] Pgp-
mediated drug transport (29), slightly reduced the decreased
drug accumulation in the MRP transfectant. This suggests
that genistein is a modulator of MRP-mediated MDR. Since
genistein is too toxic for use in patients and even too toxic to
use as a convenient reversal agent in drug resistance tests
(29), less toxic analogues of genistein that also act on MRP
are needed.
MRP in the non-Pgp MDR cell line SW-1573/2R120 is not
further increased in the Pgp-overexpressing cell line 2R160
(Fig. 4B). As this cell line was derived from 2R120 by further
selection on doxorubicin (9), the extent to which MRP
overexpression is tolerated in SW-1573 cells may be limited
to the level reached in 2R120. Consequently, MRP-mediated
MDR may play a role only in low-level MDR in SW-1573 cells
and possibly in other cells as well.
There is little information on the contribution of increased
levels of MRP to drug resistance of human cancers. High
levels ofMRP mRNA were found in leukemic cells of a high
100
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FIG. 6. Normalized cellular efflux of [G-3H]daunorubicin from
SW-1573/S1 cells (circles) or S1(MRP) cells (squares). Cells were
loaded with daunorubicin (0.5 p.M) for 60 min and suspended in
daunorubicin-free medium. At intervals thereafter, the amount of
cellular daunorubicin was measured. Two separate experiments
(closed and open symbols) are shown.
percentage of patients with chronic lymphocytic leukemia,
but there was no relation to prior chemotherapy or treatment
outcome (30). The phenotype delineated in this paper, the
anti-MRP antisera, and the methods used here to demon-
strate reduced drug accumulation should help to determine
the role of MRP-mediated MDR in clinical drug resistance.
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